APO-GABAPENTIN 400 MG
GABAPENTIN : 400 MG · DIN 02244306 · APOTEX INC
Health Canada status: MARKETED
What is APO-GABAPENTIN?
APO-GABAPENTIN 400 MG contains GABAPENTIN : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02244306, held by APOTEX INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 27-Aug-2001. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02244306 |
|---|---|
| Brand name | APO-GABAPENTIN |
| Generic / active ingredient | GABAPENTIN : 400 MG |
| Manufacturer | APOTEX INC |
| Strength | 400 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N02BF01 GABAPENTIN |
| AHFS class | 28:12.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 27-Aug-2001 |
| Original market date | 2001-08-27 00:00:00 |
Is GABAPENTIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N02BF01 GABAPENTIN. 60 of 161 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-GABAPENTIN | 100 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02244304 |
| APO-GABAPENTIN | 300 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02244305 |
| APO-GABAPENTIN | 600 MG | TABLET | APOTEX INC | MARKETED | DIN 02293358 |
| APO-GABAPENTIN | 800 MG | TABLET | APOTEX INC | MARKETED | DIN 02293366 |
| AURO-GABAPENTIN | 100 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02321203 |
| AURO-GABAPENTIN | 300 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02321211 |
| AURO-GABAPENTIN | 400 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02321238 |
| AURO-GABAPENTIN TABLETS | 600 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02428334 |
| AURO-GABAPENTIN TABLETS | 800 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02428342 |
| GABAPENTIN | 100 MG | CAPSULE | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02246314 |
Who else supplies GABAPENTIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. GABAPENTIN appears in 555 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.